ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
Clinical Trials Related to Encorafenib
Related studies linked through entity extraction aliases.
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Therapy for BRAF-V600E Metastatic CRCm
- Status
- RECRUITING
- Phase
- PHASE2
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- Status
- SUSPENDED
- Phase
- PHASE1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- Status
- RECRUITING
- Phase
- PHASE1
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
- Status
- COMPLETED
- Phase
- N/A
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1